Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1697-1708

  Jia, Yanhui ^a   Yuan, Mei ^a   Yuan, Huidong ^a   Huang, Xinglu ^b   Sui, Xiang ^a   Cui, Xuemei ^a   Tang, Fangqiong ^b   Peng, Jiang ^a   Chen, Jiying ^a   Lu, Shibi ^a   Xu, Wenjing ^a   Zhang, Li ^a   Guo, Quanyi ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY   (China)

Author keywords

Antitumor activity; Apoptosis; External magnetic field; Intratumoral injection; Lewis lung carcinoma

Indexed keywords

DOXORUBICIN; MAGNETIC NANOPARTICLE; MAGNETITE NANOPARTICLE; NANOCARRIER; POLYGLACTIN; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; NANOCONJUGATE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIODEGRADATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; EMULSION; EVAPORATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; MAGNETIC FIELD; METASTASIS; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PH MEASUREMENT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TIMED DRUG RELEASE; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; INTRALESIONAL DRUG ADMINISTRATION; NANOMEDICINE; PARTICLE SIZE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LACTIC ACID; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED C57BL; NANOCONJUGATES; NANOMEDICINE; PARTICLE SIZE; POLYGLYCOLIC ACID;

EID: 84866767380     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28629     Document Type: Article

References (47)

1. Hortobágyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs. 1997;54 Suppl 4:1-7.
2. Goodman MF, Lee GM. Adriamycin interactions with T4 DNA polymerase: two modes of template-mediated inhibition. J Biol Chem. 1977;252(8):2670-2674.
3. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7(7):687-693.
4. Yousefpour P, Atyabi F, Farahani EV, Sakhtianchi R, Dinarvand R. Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int J Nanomedicine. 2011;6:1487-1496.
5. Kang YM, Kim GH, Kim JI, et al. In vivo eff icacy of an intratumorally injected in situ-forming doxorubicin/poly(ethylene glycol)-b-polycaprolactone diblock copolymer. Biomaterials. 2011;32(20):4556-4564.
6. Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target. 2005;13(7):391-397.
7. Weinberg BD, Ai H, Blanco E, Anderson JM, Gao J. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A. 2007;81(1):161-170.
8. Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine. 2011;6:2321-2326.
9. Al-Abd AM, Hong KY, Song SC, Kuh HJ. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release. 2010;142(1):101-107.
10. Xie M, Zhou L, Hu T, Yao M. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts. Anticancer Drugs. 2007;18(4): 459-466.
11. Emerich DF, Snodgrass P, Lafreniere D, et al. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res. 2002;19(7):1052-1060.
12. Chang GT, Li C, Lu WY, Ding JD. N-Boc-histidine-capped PLGAPEG-PLGA as a smart polymer for drug delivery sensitive to tumor extracellular pH. Macromol Biosci. 2010;10(10):1248-1256.
13. Xu XL, Chen XS, Wang ZF, Jing XB. Ultrafine PEG-PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity. Eur J Pharm Biopharm. 2009;72(1):18-25.
14. Xie J, Huang J, Li X, Sun S, Chen X. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem. 2009;16(10):1278-1294.
15. 3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine. 2009;4: 65-71.
16. Wang J, Chen Y, Chen B, et al. Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine. 2010;5:861-866.
17. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293(1):483-496.
18. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2(3):22-32.
19. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008;3(2):169-180.
20. Widder KJ, Morris RM, Poore G, Howard DP Jr, Senyei AE. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc Natl Acad Sci U S A. 1981;78(1):579-581.
21. Lübbe AS, Bergemann C, Huhnt W, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996; 56(20):4694-4701.
22. Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4d-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56(20):4686-4693.
23. Alexiou C, Jurgons R, Schmid RJ, et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target. 2003;11(3):139-149.
24. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
25. Murakami T, Tsuchida K, Hashida M, Imahori H. Size control of lipid-based drug carrier by drug loading. Mol Biosyst. 2010;6(5): 789-791.
26. Patil RR, Guhagarkar SA, Devarajan PV. Engineered nanocarriers of doxorubicin: a current update. Crit Rev Ther Drug Carrier Syst. 2008; 25(1):1-61.
27. Kataoka K, Matsumoto T, Yokoyama M, et al. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release. 2000;64(1-3):143-153.
28. Springate CM, Jackson JK, Gleave ME, Burt HM. Clusterin antisense complexed with chitosan for controlled intratumoral delivery. Int J Pharm. 2008;350(1-2):53-64.
29. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18): 3995-4021.
30. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165-1170.
31. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul. 1996;13(3): 245-255.
32. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-1603.
33. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release. 2000;68(3):419-431.
34. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6(1):15-19.
35. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373-4384.
36. Wang H, Zhao Y, Wu Y, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32(32):8281-8290.
37. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14(11):1568-1573.
38. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3): 329-347.
39. Jordan A, Scholz R, Schnoy N, Wust P, Maier-Hauff K, Felix R. Differential endocytosis of magnetic fluid particles into human primary glioblastoma, neuronal and fibroblast cells in vitro. Eur J Cell Biol. 1997;(Suppl 47):32.
40. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23(11):1418-1423.
41. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 2005;21(19):8858-8864.
42. Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials. 2010;31(3):438-448.
43. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small. 2006;2(6): 785-792.
44. 3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009;4:73-78.
45. 4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009;4:107-114.
46. Widder KJ, Senyei AE, Ranney DF. In vitro release of biologically active Adriamycin by magnetically responsive albumin microspheres. Cancer Res. 1980;40(10):3512-3517.
47. Gupta PK, Hung CT. Magnetically controlled targeted chemotherapy. In: Willmott N, Daly J, editors. Microspheres and Regional Cancer Therapy. Boca Raton, FL: CRC Press; 1993:71-116.